AlloVir Future Growth
Future criteria checks 0/6
AlloVir is forecast to grow earnings at 24.5% per annum. EPS is expected to grow by 25.7% per annum.
Key information
24.5%
Earnings growth rate
25.7%
EPS growth rate
Biotechs earnings growth | 30.0% |
Revenue growth rate | n/a |
Future return on equity | -33.1% |
Analyst coverage | Low |
Last updated | 13 Aug 2024 |
Recent future growth updates
Recent updates
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Jul 13We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11AlloVir GAAP EPS of $0.69 beats by $1.42
Aug 04AlloVir stock surges on $126.6M securities offering
Jul 27Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Mar 21AlloVir: A Comparative Study Of Its Manufacturing Process
Feb 07We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate
Nov 02AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
Oct 02AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 06We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Jul 01AlloVir EPS misses by $0.08
May 06AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans
Apr 01This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)
Feb 07Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
Jan 08FDA clears AlloVir's ALVR106 application in respiratory viruses
Dec 17Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data
Dec 07We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Dec 04AlloVir EPS misses by $0.28
Nov 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -54 | N/A | N/A | 1 |
12/31/2025 | N/A | -41 | N/A | N/A | 2 |
12/31/2024 | N/A | -48 | N/A | N/A | 2 |
6/30/2024 | N/A | -140 | -121 | -121 | N/A |
3/31/2024 | N/A | -180 | -137 | -137 | N/A |
12/31/2023 | N/A | -190 | -124 | -124 | N/A |
9/30/2023 | N/A | -169 | -125 | -125 | N/A |
6/30/2023 | N/A | -167 | -126 | -126 | N/A |
3/31/2023 | N/A | -166 | -128 | -128 | N/A |
12/31/2022 | N/A | -169 | -142 | -142 | N/A |
9/30/2022 | N/A | -189 | -138 | -139 | N/A |
6/30/2022 | N/A | -192 | -140 | -140 | N/A |
3/31/2022 | N/A | -185 | -134 | -134 | N/A |
12/31/2021 | N/A | -172 | -106 | -106 | N/A |
9/30/2021 | N/A | -139 | -100 | -99 | N/A |
6/30/2021 | N/A | -117 | -82 | -81 | N/A |
3/31/2021 | N/A | -91 | -70 | -69 | N/A |
12/31/2020 | N/A | -70 | -61 | -61 | N/A |
9/30/2020 | N/A | -53 | -49 | -49 | N/A |
6/30/2020 | N/A | -37 | -37 | -37 | N/A |
3/31/2020 | N/A | -31 | -29 | -29 | N/A |
12/31/2019 | 0 | -24 | -20 | -20 | N/A |
12/31/2018 | 1 | -8 | 2 | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALVR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALVR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALVR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ALVR's revenue is forecast to grow faster than the US market.
High Growth Revenue: ALVR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALVR is forecast to be unprofitable in 3 years.